Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | TTR | P02766 | 1/20 | 0.53 |
| ▸ | PTPRC | P08575 | 2/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TERT | O14746 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31268599 | 0.92 | S100A4 (0.86) | S100A4NPC1RAB9AMAPTTTR | |
| SCHEMBL10530992 | 0.92 | TTR (0.67) | S100A4NPC1RAB9AMAPTTTR | |
| SCHEMBL8014885 | 0.92 | S100A4 (0.86) | S100A4NPC1RAB9AMAPTTTR | |
| SCHEMBL10881228 | 0.90 | S100A4 (0.82) | S100A4NPC1RAB9AMAPTTTR | |
| SCHEMBL8033807 | 0.88 | S100A4 (0.73) | S100A4NPC1RAB9AMAPTPTPRC | |
| SCHEMBL6259661 | 0.88 | S100A4 (0.93) | S100A4NPC1RAB9AMAPTTTR | |
| SCHEMBL9423385 | 0.88 | S100A4 (0.93) | S100A4NPC1RAB9AMAPTTTR | |
| Dimethylamine SCHEMBL7241455 | 0.87 | S100A4 (0.77) | S100A4NPC1RAB9AMAPTTTR | |
| SCHEMBL5820822 | 0.85 | S100A4 (0.65) | S100A4NPC1RAB9AMAPTTTR | |
| SCHEMBL2599394 | 0.84 | S100A4 (1.00) | S100A4NPC1RAB9AMAPTTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872236-B2 | Pharmacological agents for treating ocular diseases | CALASIA PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872236-B2 | Pharmacological agents for treating ocular diseases | CALASIA PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20210154213-A1 | PHARMACOLOGICAL AGENTS FOR TREATING OCULAR DISEASES | CALASIA PHARMACEUTICALS INC (US) | 2021-05-27 | — | — | US | disclosed |
| US-4496447-A | PHOTOPOLYMERIZATION OF UNSATURATED COMPOUNDS AND FOR CURING PRINTING INKS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1985-01-29 | — | — | US | disclosed |
| US-4374984-A | Aromatic-aliphatic ketones useful as photoinitiators | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154213-A1 | PHARMACOLOGICAL AGENTS FOR TREATING OCULAR DISEASES | CRYAA, CRYAB, TTR | S100A4 128/4885NPC1 1876/4885RAB9A 1655/4885 |
| US-11872236-B2 | Pharmacological agents for treating ocular diseases | CRYAA, CRYAB, TTR | S100A4 128/4885NPC1 1876/4885RAB9A 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.